FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760661635> ?p ?o ?g. }

• W2760661635 endingPage "1492" @default.
• W2760661635 startingPage "1483" @default.
• W2760661635 abstract "Background More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. We assessed the activity and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer. Methods In this multicentre, single-arm, phase 2 study (KEYNOTE-052), cisplatin-ineligible patients with advanced urothelial cancer who had not been previously treated with systemic chemotherapy were recruited from 91 academic medical centres in 20 countries. Enrolled patients received intravenous pembrolizumab 200 mg every 3 weeks. The primary endpoint was objective response (the proportion of patients who achieved complete or partial response) in all patients and by PD-L1 expression status according to the Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by independent central review. PD-L1 expression was assessed in tumour and inflammatory cells from tumour biopsies provided at study entry. Activity and safety were analysed in all patients who received at least one dose of pembrolizumab (all-patients-treated population). This study is registered with ClinicalTrials.gov, number NCT02335424, and follow-up is ongoing. Findings Between Feb 24, 2015, and Aug 8, 2016, 374 patients were enrolled and 370 patients received at least one dose of pembrolizumab. 89 (24%, 95% CI 20–29) of 370 patients had a centrally assessed objective response, and as of Sept 1, 2016 (data cutoff), 74 (83%) of 89 responses were ongoing. Median follow-up was 5 months (IQR 3·0–8·6). A PD-L1-expression cutoff of 10% was associated with a higher frequency of response to pembrolizumab; 42 (38%, 95% CI 29–48) of 110 patients with a combined positive score of 10% or more had a centrally assessed objective response. The most common grade 3 or 4 treatment-related adverse events were fatigue (eight [2%] of 370 patients), alkaline phosphatase increase (five [1%]), colitis, and muscle weakness (both four [1%]). 36 (10%) of 370 patients had a serious treatment-related adverse event. 17 (5%) of 370 patients died from non-treatment-related adverse events associated with death, and one patient died from treatment-related adverse events (myositis in addition to grade 3 thyroiditis, grade 3 hepatitis, grade 3 pneumonia, and grade 4 myocarditis). Interpretation First-line pembrolizumab has antitumour activity and acceptable tolerability in cisplatin-ineligible patients with urothelial cancer, most of whom were elderly, had poor prognostic factors, or had serious comorbidities. In view of this result, pembrolizumab has become a new treatment option for patients who are cisplatin-ineligible or not suitable candidates for chemotherapy. Pembrolizumab in the first-line setting is being further assessed in the phase 3 KEYNOTE-361 trial (ClinicalTrials.gov, NCT02335424). Funding Merck & Co." @default.
• W2760661635 created "2017-10-06" @default.
• W2760661635 creator A5001308517 @default.
• W2760661635 creator A5010923222 @default.
• W2760661635 creator A5018398274 @default.
• W2760661635 creator A5021767773 @default.
• W2760661635 creator A5024147987 @default.
• W2760661635 creator A5026717218 @default.
• W2760661635 creator A5032422193 @default.
• W2760661635 creator A5041610986 @default.
• W2760661635 creator A5064884168 @default.
• W2760661635 creator A5066133616 @default.
• W2760661635 creator A5068785092 @default.
• W2760661635 creator A5071418777 @default.
• W2760661635 creator A5072911394 @default.
• W2760661635 creator A5074756323 @default.
• W2760661635 creator A5082741754 @default.
• W2760661635 date "2017-11-01" @default.
• W2760661635 modified "2023-10-14" @default.
• W2760661635 title "First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study" @default.
• W2760661635 cites W1478180867 @default.
• W2760661635 cites W1893740135 @default.
• W2760661635 cites W1982488143 @default.
• W2760661635 cites W1990675339 @default.
• W2760661635 cites W2046702136 @default.
• W2760661635 cites W2066671159 @default.
• W2760661635 cites W2120955645 @default.
• W2760661635 cites W2131577873 @default.
• W2760661635 cites W2135821800 @default.
• W2760661635 cites W2148562299 @default.
• W2760661635 cites W2152575748 @default.
• W2760661635 cites W2152762320 @default.
• W2760661635 cites W2155464214 @default.
• W2760661635 cites W2289712604 @default.
• W2760661635 cites W2304807567 @default.
• W2760661635 cites W2345415641 @default.
• W2760661635 cites W2401455386 @default.
• W2760661635 cites W2414977199 @default.
• W2760661635 cites W2530516001 @default.
• W2760661635 cites W2559804019 @default.
• W2760661635 cites W2570159314 @default.
• W2760661635 cites W2582671354 @default.
• W2760661635 cites W2588916311 @default.
• W2760661635 doi "https://doi.org/10.1016/s1470-2045(17)30616-2" @default.
• W2760661635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28967485" @default.
• W2760661635 hasPublicationYear "2017" @default.
• W2760661635 type Work @default.
• W2760661635 sameAs 2760661635 @default.
• W2760661635 citedByCount "940" @default.
• W2760661635 countsByYear W27606616352017 @default.
• W2760661635 countsByYear W27606616352018 @default.
• W2760661635 countsByYear W27606616352019 @default.
• W2760661635 countsByYear W27606616352020 @default.
• W2760661635 countsByYear W27606616352021 @default.
• W2760661635 countsByYear W27606616352022 @default.
• W2760661635 countsByYear W27606616352023 @default.
• W2760661635 crossrefType "journal-article" @default.
• W2760661635 hasAuthorship W2760661635A5001308517 @default.
• W2760661635 hasAuthorship W2760661635A5010923222 @default.
• W2760661635 hasAuthorship W2760661635A5018398274 @default.
• W2760661635 hasAuthorship W2760661635A5021767773 @default.
• W2760661635 hasAuthorship W2760661635A5024147987 @default.
• W2760661635 hasAuthorship W2760661635A5026717218 @default.
• W2760661635 hasAuthorship W2760661635A5032422193 @default.
• W2760661635 hasAuthorship W2760661635A5041610986 @default.
• W2760661635 hasAuthorship W2760661635A5064884168 @default.
• W2760661635 hasAuthorship W2760661635A5066133616 @default.
• W2760661635 hasAuthorship W2760661635A5068785092 @default.
• W2760661635 hasAuthorship W2760661635A5071418777 @default.
• W2760661635 hasAuthorship W2760661635A5072911394 @default.
• W2760661635 hasAuthorship W2760661635A5074756323 @default.
• W2760661635 hasAuthorship W2760661635A5082741754 @default.
• W2760661635 hasConcept C121608353 @default.
• W2760661635 hasConcept C126322002 @default.
• W2760661635 hasConcept C143998085 @default.
• W2760661635 hasConcept C203092338 @default.
• W2760661635 hasConcept C2776694085 @default.
• W2760661635 hasConcept C2776907518 @default.
• W2760661635 hasConcept C2777701055 @default.
• W2760661635 hasConcept C2778239845 @default.
• W2760661635 hasConcept C2779984678 @default.
• W2760661635 hasConcept C2780057760 @default.
• W2760661635 hasConcept C2780352672 @default.
• W2760661635 hasConcept C2908647359 @default.
• W2760661635 hasConcept C2911057145 @default.
• W2760661635 hasConcept C3019882237 @default.
• W2760661635 hasConcept C3020745361 @default.
• W2760661635 hasConcept C31760486 @default.
• W2760661635 hasConcept C535046627 @default.
• W2760661635 hasConcept C71924100 @default.
• W2760661635 hasConcept C99454951 @default.
• W2760661635 hasConceptScore W2760661635C121608353 @default.
• W2760661635 hasConceptScore W2760661635C126322002 @default.
• W2760661635 hasConceptScore W2760661635C143998085 @default.
• W2760661635 hasConceptScore W2760661635C203092338 @default.
• W2760661635 hasConceptScore W2760661635C2776694085 @default.
• W2760661635 hasConceptScore W2760661635C2776907518 @default.
• W2760661635 hasConceptScore W2760661635C2777701055 @default.

• next